ES2570769T3 - Triazolopiridinas como inhibidores fosfodiesterasa para el tratamiento de enfermedades dérmicas - Google Patents

Triazolopiridinas como inhibidores fosfodiesterasa para el tratamiento de enfermedades dérmicas

Info

Publication number
ES2570769T3
ES2570769T3 ES09795687T ES09795687T ES2570769T3 ES 2570769 T3 ES2570769 T3 ES 2570769T3 ES 09795687 T ES09795687 T ES 09795687T ES 09795687 T ES09795687 T ES 09795687T ES 2570769 T3 ES2570769 T3 ES 2570769T3
Authority
ES
Spain
Prior art keywords
alkyl
cycloalkyl
nr7r8
aryl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09795687T
Other languages
English (en)
Inventor
Simon Feldbæk Nielsen
Thomas Vifian
Anne Marie Horneman
Jesper Færgemann Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Application granted granted Critical
Publication of ES2570769T3 publication Critical patent/ES2570769T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de la fórmula general I, **Fórmula** en donde R1 es alcoxi C1-6, tal como metoxi, mono-, di- o trifluorometoxi, halógeno, o hidroxi; R2 es alquilo, cicloalquilo, alquilcicloalquilo, o cicloalquilo(C(O)NR7R8), cada uno de los cuáles se sustituye opcionalmente con uno o más sustituyentes seleccionados de R4; R3 es hidrógeno, halógeno, arilo, heteroarilo, hidroxi, alquilo, cicloalquilo, heterocicloalquilo, alcoxi, oxo, ciano, amino, aminoalquilo, alquilamino o dialquilamino; R4 es hidrógeno, halógeno, hidroxi, oxo, ciano, carboxi, o trihalometilo, o R4 es NR5R6,-C(O)NR7R8 ,-C(O)R7,-COOR7,-NR5C(O)NR7R8,-OC(O)NR7R8,-OC(O)R3, NC(O)R7,-OR7,-NC(O)OR3,-NSO2R7,-SO2NR7R8, o-SO2R,R8, alquilo, cicloalquilo, alquenilo, alquinilo, arilo, heteroarilo, cicloalquilalquilo, cicloalquilalquenilo, cicloalquilalquinilo, cicloalquenilalquilo, cicloalquenilalquenilo, cicloalquenilalquinilo, heterocicloalquilo, heterocicloalquilalquilo, heterocicloalquenilo, heterocicloalquenilalquilo, heterocicloalquenilalquenilo, heterocicloalquenilalquinilo, arilalquilo, arilalquenilo, arilalquinilo, heteroarilalquilo, heteroarilalquenilo, heteroarilalquinilo, alcoxi, cicloalquiloxi, alquiltio, cicloalquiltio, sulfamoilo, sulfinamoilo, alquilamino o cicloalquilamino, cada uno de los cuáles se sustituye opcionalmente con uno o más sustituyentes seleccionados de R9; R5 y R6 cada uno representa independientemente hidrógeno, alquilo, alquenilo, cicloalquilo, heterocicloalquilo,-C(O)alquilo,-C(O)Oalquilo,-C(O)cicloalquilo,-C(O)N-alquilo, carboxialquilo,-C(O)alquil-C(O)OH,-C(O)alquil-C(O)N-alquilo,-C(O)Narilo,-S(O)2alquilo,-S(O)alquilo,-S(O)2arilo,-S(O)2N-alquilo,-S(O)arilo, arilo, heteroaril alquilarilo o alquilheteroarilo, cada uno de los cuáles se sustituye opcionalmente con hidroxi o una o más halógenos, o R5 y R6 juntos con el átomo de nitrógeno al que se unen forman un anillo heterocicloalquilo, en donde dicho anillo se sustituye opcionalmente con uno o más grupos alquilo; R7 y R8 cada uno representa independientemente hidrógeno, alquilo, cicloalquilo, alquenilo, heteroarilo, heterocicloalquilo, carboxialquilo, carbamoilalquilo, alquiloxialquilo, alqueniloxialquilo, arilo, arilalquilo, alquilarilo, heteroarilo, heteroarilalquilo, o alquilheteroarilo, cada uno de los cuáles se sustituye opcionalmente con uno o más sustituyentes seleccionados del grupo que consiste de hidroxi, halógeno, oxo, ciano, alquilo, cicloalquilo, alquenilo, alcoxi, arilo, heteroarilo, heterocicloalquilo,-S(O)2-alquilo,-S(O)2-N11R12,-NC(O)-alquilo,-C(O)N-alquilo,-NC(O)O-35 alquilo,-OC(O)N-alquilo,-NC(O)N11R12,-N11SO2-alquilo,-S(O)-alquilo, o R7 y R8 juntos con el átomo de nitrógeno al que se unen forman un anillo heterocicloalquilo, en donde dicho anillo se sustituye opcionalmente con uno o más grupos alquilo; R9 es hidrógeno, halógeno, hidroxi, alcoxi, carboxi o trihalometilo; X y Y son C y N o N y C, respectivamente; A es arilo, cicloalquilo, cicloalquenilo, heteroarilo, heterocicloalquilo o heterocicloalquenilo, cada uno se sustituye opcionalmente con uno o más sustituyentes seleccionados del grupo que consiste de R10; R10 es hidrógeno, ciano, halógeno, hidroxi, u oxo, o R10 es alquilo, cicloalquilo, alquenilo, alquinilo, arilo, heteroarilo, cicloalquilalquilo, cicloalquilalquenilo, cicloalquilalquinilo, cicloalquenilalquilo, cicloalquenilalquenilo, cicloalquenilalquinilo, heterocicloalquilo, heterocicloalquenilo, heterocicloalquenilalquilo, heterocicloalquenilalquenilo, heterocicloalquenilalquinilo, arilalquilo, arilalquenilo, arilalquinilo, heteroarilalquilo, heteroarilalquenilo, heteroarilalquinilo, alcoxi, cicloalquiloxi, alquiltio, cicloalquiltio,-S(O)alquilo,-S(O)2-alquilo, sulfamoilo, sulfinamoilo,-C(O)OR3,-C(O)R3,-NR5R6,-alquilo(NR5R6),-cicloalquilo(NR5R6),-cicloalquilalquilo(NR5R6),-alquilcicloalquilo(NR5R6),-C(O)NR7R8,-alquilo(C(O)NR7R8-cicloalquilo(C(O)NR7R8),-cicloalquilalquilo(C(O)NR7R8) o-alquilcicloalquilo(C(O)NR7R8), cada uno de los cuáles se sustituye opcionalmente con uno o más sustituyentes seleccionados de R4; 11 y R12 cada uno representa independientemente hidrógeno o alquilo; y sales farmacéuticamente aceptables, hidratos, óxidos N o solvatos de los mismos.
ES09795687T 2008-12-19 2009-12-18 Triazolopiridinas como inhibidores fosfodiesterasa para el tratamiento de enfermedades dérmicas Active ES2570769T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13944508P 2008-12-19 2008-12-19
PCT/DK2009/000262 WO2010069322A1 (en) 2008-12-19 2009-12-18 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Publications (1)

Publication Number Publication Date
ES2570769T3 true ES2570769T3 (es) 2016-05-20

Family

ID=41693461

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09795687T Active ES2570769T3 (es) 2008-12-19 2009-12-18 Triazolopiridinas como inhibidores fosfodiesterasa para el tratamiento de enfermedades dérmicas

Country Status (25)

Country Link
US (1) US8952162B2 (es)
EP (1) EP2379548B1 (es)
JP (2) JP5743901B2 (es)
KR (1) KR20110094355A (es)
CN (1) CN102317287B (es)
AU (1) AU2009328752B2 (es)
BR (1) BRPI0922452A2 (es)
CA (1) CA2747022A1 (es)
CY (1) CY1117562T1 (es)
DK (1) DK2379548T3 (es)
ES (1) ES2570769T3 (es)
HK (1) HK1165791A1 (es)
HR (1) HRP20160488T1 (es)
HU (1) HUE027770T2 (es)
IL (1) IL213570A (es)
MX (1) MX2011006428A (es)
NO (1) NO20110871A1 (es)
NZ (1) NZ593595A (es)
PL (1) PL2379548T3 (es)
RS (1) RS54752B1 (es)
RU (1) RU2544011C2 (es)
SG (1) SG172206A1 (es)
SI (1) SI2379548T1 (es)
WO (1) WO2010069322A1 (es)
ZA (1) ZA201104422B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1009637A2 (pt) 2009-06-05 2019-04-30 Cephalon, Inc composto, composição e uso de um composto
ME01858B (me) 2009-07-17 2014-12-20 Japan Tobacco Inc Jedinjenje triazolopiridina i njegovo dejstvo kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
AU2010335656B2 (en) 2009-12-22 2015-05-07 Leo Pharma A/S Pharmaceutical composition comprising solvent mixture and a vitamin D derivative or analogue
RU2555339C2 (ru) 2009-12-22 2015-07-10 Лео Фарма А/С Нанокристаллы кальципотриола моногидрита
AU2010335654B2 (en) 2009-12-22 2015-04-09 Leo Pharma A/S Cutaneous composition comprising vitamin D analogue and a mixture of solvent and surfactants
ES2711100T3 (es) * 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
CA2858123A1 (en) 2011-12-21 2013-06-27 Leo Pharma A/S [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors
EP2925364A1 (en) * 2012-11-30 2015-10-07 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
WO2014206903A1 (en) 2013-06-25 2014-12-31 Leo Pharma A/S METHODS FOR THE PREPARATION OF SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIDINES
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
FI3724196T3 (fi) 2017-12-15 2023-01-31 Substituoituja atsetidiinidihydrotienopyridiinejä ja niiden käyttö fosfodiesteraasin estäjinä
JP2021155336A (ja) * 2018-06-27 2021-10-07 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤
AR114977A1 (es) * 2018-06-27 2020-11-11 Meiji Seika Pharma Co Ltd Cristales de derivado de benzoxazol

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771794B1 (en) 1995-05-19 2006-05-03 Kyowa Hakko Kogyo Co., Ltd. Oxygen-containing heterocyclic compounds
CA2272327A1 (en) 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygen-containing heterocyclic compounds
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
JP4890439B2 (ja) * 2005-03-07 2012-03-07 杏林製薬株式会社 ピラゾロピリジン−４−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2007091597A (ja) * 2005-09-27 2007-04-12 Kyorin Pharmaceut Co Ltd ピラゾロピリジン−４−イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤
US20090196284A1 (en) * 2006-06-28 2009-08-06 Nokia Siemens Networks Gmbh & Co.Kg Method for Providing an Emergency Call Service for VoIP Subscribers
US20100035756A1 (en) * 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
JP2008024599A (ja) * 2006-07-18 2008-02-07 Kyorin Pharmaceut Co Ltd ピリダジノン誘導体、それらを有効成分とするｐｄｅ阻害剤及び医薬
JP2008069144A (ja) * 2006-08-17 2008-03-27 Kyorin Pharmaceut Co Ltd ピラゾロン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
CN101679428A (zh) 2007-04-16 2010-03-24 利奥制药有限公司 用于治疗皮肤疾病的作为磷酸二酯酶抑制剂的三唑并吡啶类
WO2008156102A1 (ja) * 2007-06-19 2008-12-24 Kyorin Pharmaceutical Co., Ltd. ピラゾロン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
CA2692248A1 (en) * 2007-06-19 2008-12-24 Kyorin Pharmaceutical Co., Ltd. Pyridazinone derivative and pde inhibitor containing the same as active ingredient
JP2009040711A (ja) 2007-08-08 2009-02-26 Kyorin Pharmaceut Co Ltd カルボスティリル誘導体及びそれらを有効成分とするｐｄｅ阻害剤
WO2010035745A1 (ja) 2008-09-25 2010-04-01 杏林製薬株式会社 ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
US20110224250A1 (en) 2008-10-09 2011-09-15 Yasushi Kohno Isoquinoline derivative, and pde inhibitor comprising same as active ingredient

Also Published As

Publication number Publication date
SG172206A1 (en) 2011-07-28
CN102317287B (zh) 2014-10-08
KR20110094355A (ko) 2011-08-23
RU2544011C2 (ru) 2015-03-10
JP5743901B2 (ja) 2015-07-01
IL213570A (en) 2015-10-29
DK2379548T3 (en) 2016-05-17
JP2015096535A (ja) 2015-05-21
SI2379548T1 (sl) 2016-06-30
CA2747022A1 (en) 2010-06-24
JP2012512192A (ja) 2012-05-31
MX2011006428A (es) 2011-07-28
HRP20160488T1 (hr) 2016-06-17
CY1117562T1 (el) 2017-04-26
BRPI0922452A2 (pt) 2015-12-15
NO20110871A1 (no) 2011-09-19
RS54752B1 (sr) 2016-10-31
HK1165791A1 (en) 2012-10-12
AU2009328752B2 (en) 2015-07-16
PL2379548T3 (pl) 2016-08-31
IL213570A0 (en) 2011-07-31
HUE027770T2 (en) 2016-11-28
US8952162B2 (en) 2015-02-10
ZA201104422B (en) 2012-09-26
US20120028974A1 (en) 2012-02-02
AU2009328752A1 (en) 2011-07-07
NZ593595A (en) 2013-07-26
EP2379548B1 (en) 2016-03-09
CN102317287A (zh) 2012-01-11
WO2010069322A1 (en) 2010-06-24
EP2379548A1 (en) 2011-10-26

Similar Documents

Publication Publication Date Title
ES2570769T3 (es) Triazolopiridinas como inhibidores fosfodiesterasa para el tratamiento de enfermedades dérmicas
AR060506A1 (es) Compuestos organicos
CO5690643A2 (es) Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos
SI9110396B (sl) Derivati N-(4-piperidinil)(dihidrobenzofuran ali dihidro-2H-benzopiran) karboksamida
NZ532494A (en) Dibenzylamine compound and medicinal use thereof
AR075005A1 (es) Derivados de sulfonamida
PE20030137A1 (es) Derivados antimicrobianos de quinolona
RS53670B1 (en) TRIAZOLOPIRIMIDINI
AR051514A1 (es) Derivados de pirido[2, 1 - a]isoquinolina sustituidos como inhibidores de dpp-iv; un proceso para su elaboracion; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de distintos tipos de diabetes y de intolerancia a la glucosa.
EP1867331A4 (en) TRIAZOL DERIVATIVE AND ITS USE
AR049331A1 (es) Derivados de imidazopiridinas, imidazoquinolinas e iimidazonaftiridinas sustituidas con amidas como moduladores de biosintesis de citoquinas. composiciones farmaceuticas.
WO2005037783A3 (fr) Composes tricycliques comme inhibiteurs de transport de glycine
AR045219A1 (es) Aminas ciclicas inhibidoras de base - 1 que poseen un sustiuyente heterociclico
AR045260A1 (es) Compuestos que contienen imidazo-oxima sustituidos
MD20110063A2 (en) Herbicidal compositions containing benzoylpyrazole compounds
AR074435A1 (es) Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.
PE20091085A1 (es) NUEVOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA E IMIDAZO[1,2-b]-PIRIDAZINA
CO5601018A2 (es) Derivados de n-fenil-2-pirimidin-amina
EP2144980A1 (en) Lubricant antioxidant compositions containing a metal compound and a hindered amine
YU57086A (en) Process for making antibacterial azole compounds
DE60318583D1 (de) N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
AR079250A1 (es) Derivados de pirazolo[1,5-a]piridina utiles en el tratamiento de enfermedades del snc y canceres, composiciones farmaceuticas que los contienen e intermediario de sintesis.
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
CO5660271A2 (es) Preparacion de peptidos de somatostatina